Regulatory Factor X 5 (RFX5) Peptide
RFX5
Reactivity: Human
Host: Synthetic
BP, WB
Catalog No. ABIN982894
Quick Overview for Regulatory Factor X 5 (RFX5) Peptide (ABIN982894)
Target
RFX5
(Regulatory Factor X 5 (RFX5))
Origin
Human
Source
Synthetic
Application
Blocking Peptide (BP), Western Blotting (WB)
-
-
Characteristics
- This is a synthetic peptide designed for use in combination with anti-RFX5 antibody (Catalog #: ARP37992_T100). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
-
Purification
- Purified
-
-
-
-
Application Notes
- Each Investigator should determine their own optimal working dilution for specific applications.
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Reconstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
-
Concentration
- 1 mg/mL
-
Buffer
- Final peptide concentration is 1 mg/mL in PBS.
-
Handling Advice
- Avoid repeated freeze-thaw cycles.
-
Storage
- -20 °C
-
Storage Comment
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
-
- RFX5 (Regulatory Factor X 5 (RFX5))
-
Background
-
RFX5 is the fifth member of the growing family of DNA-binding proteins sharing a novel and highly characteristic DNA-binding domain called the RFX motif. RFX is a nuclear protein complex that binds to the X box of MHC-II promoters. The lack of RFX binding activity in complementation group C results from mutations in the RFX5 gene encoding the 75-kD subunit of RFX.A lack of MHC-II expression results in a severe immunodeficiency syndrome called MHC-II deficiency, or the bare lymphocyte syndrome (BLS, MIM 209920). At least 4 complementation groups have been identified in B-cell lines established from patients with BLS. The molecular defects in complementation groups B, C, and D all lead to a deficiency in RFX.A lack of MHC-II expression results in a severe immunodeficiency syndrome called MHC-II deficiency, or the bare lymphocyte syndrome (BLS, MIM 209920). At least 4 complementation groups have been identified in B-cell lines established from patients with BLS. The molecular defects in complementation groups B, C, and D all lead to a deficiency in RFX, a nuclear protein complex that binds to the X box of MHC-II promoters. The lack of RFX binding activity in complementation group C results from mutations in the RFX5 gene encoding the 75-kD subunit of RFX (Steimle et al., 1995). RFX5 is the fifth member of the growing family of DNA-binding proteins sharing a novel and highly characteristic DNA-binding domain called the RFX motif. Multiple alternatively spliced transcript variants have been found but the full-length natures of only two have been determined.
Protein Interaction Partner: CIITA,HDAC2,RFXANK,RFXAP,CIITA,RFXANK,RFXAP
Protein Size: 616 -
Molecular Weight
- 68 kDa
-
Gene ID
- 5993
-
NCBI Accession
- NM_001025603, NP_001020774
-
UniProt
- P48382
Target
-
You are here:
